Development of build-in adjuvant peptide vaccine bearing lipid A mimic

为了通过与糖脂的偶联来提高肽的抗原性，基于类脂A（Toll样受体4激动剂）的结构设计了一种糖脂复合物，用于构建佐剂型亚单位肽疫苗。在固相肽合成过程中，通过接头将合成的糖脂与源自甲型流感病毒膜蛋白胞外结构域的M2e抗原缀合，产生糖脂缀合的M2e作为内置疫苗候选物。糖脂缀合的M2e的免疫学评价通过小鼠免疫进行，而无需额外的佐剂。通过单独施用糖脂缀合的M2e诱导M2e特异性抗体，这意味着所设计的糖脂可用于内置佐剂疫苗开发。

Aiming at improvement of peptide antigenicity by conjugation with glycolipid, a glycolipid compound was designed based on the structure of lipid A (Toll-like receptor 4 agonist) for applying to the build-in adjuvant subunit peptide vaccine. The synthesized glycolipid was conjugated with M2e antigen derived from the extracellular domain of influenza A virus membrane protein via a linker during solid phase peptide synthesis, yielded glycolipid-conjugated M2e as a build-in vaccine candidate. Immunological evaluation of the glycolipid-conjugated M2e was carried out by mice immunization without additional adjuvant. The M2e-specific antibody was induced by administration of the glycolipid-conjugated M2e alone, meaning the designed glycolipid was useful for build-in adjuvant vaccine development.